Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) was the target of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 3,950,000 shares, a decline of 7.7% from the August 15th total of 4,280,000 shares. Approximately 5.5% of the shares of the company are short sold. Based on an average daily trading volume, of 502,500 shares, the short-interest ratio is currently 7.9 days.
Wall Street Analysts Forecast Growth
IART has been the topic of several research reports. Morgan Stanley dropped their price target on Integra LifeSciences from $59.00 to $58.00 and set an “equal weight” rating on the stock in a report on Thursday, August 25th. TheStreet downgraded Integra LifeSciences from a “b-” rating to a “c+” rating in a report on Friday, July 8th. Piper Sandler decreased their price target on Integra LifeSciences from $55.00 to $50.00 in a research report on Wednesday, August 24th. Finally, Truist Financial decreased their price target on Integra LifeSciences from $70.00 to $56.00 and set a “hold” rating for the company in a research report on Wednesday, July 20th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Integra LifeSciences has a consensus rating of “Hold” and an average target price of $65.43.
Insider Transactions at Integra LifeSciences
In related news, Director Raymond G. Murphy sold 8,000 shares of the business’s stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $55.78, for a total transaction of $446,240.00. Following the sale, the director now owns 40,825 shares of the company’s stock, valued at $2,277,218.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, EVP Lisa Evoli sold 1,165 shares of the business’s stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $55.81, for a total transaction of $65,018.65. Following the sale, the executive vice president now owns 17,997 shares of the company’s stock, valued at $1,004,412.57. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Raymond G. Murphy sold 8,000 shares of the business’s stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $55.78, for a total value of $446,240.00. Following the sale, the director now directly owns 40,825 shares in the company, valued at approximately $2,277,218.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 9,602 shares of company stock worth $536,067. Company insiders own 4.20% of the company’s stock.
Institutional Investors Weigh In On Integra LifeSciences
Integra LifeSciences Trading Up 0.1 %
NASDAQ:IART opened at $45.59 on Tuesday. Integra LifeSciences has a 1-year low of $45.18 and a 1-year high of $74.98. The firm has a market capitalization of $3.81 billion, a price-to-earnings ratio of 23.14, a price-to-earnings-growth ratio of 1.51 and a beta of 1.12. The company has a quick ratio of 2.76, a current ratio of 3.85 and a debt-to-equity ratio of 0.90. The stock has a fifty day simple moving average of $52.26 and a 200 day simple moving average of $57.70.
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.
- Get a free copy of the StockNews.com research report on Integra LifeSciences (IART)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.